

## Supplemental Data

### Maternal and fetal pharmacokinetic analysis of cannabidiol during pregnancy in mice

Wataru Ochiai\*<sup>1</sup>, Satoshi Kitaoka<sup>1</sup>, Taisuke Kawamura<sup>1</sup>, Jo Hatogai<sup>1</sup>, Shohei Harada<sup>1</sup>, Misa Iizuka<sup>1</sup>, Mashu Ariumi<sup>1</sup>, Seiya Takano<sup>1</sup>, Tomomi Nagai<sup>1</sup>, Masanaho Sasatsu<sup>2</sup>, Kiyoshi Sugiyama<sup>3</sup>

<sup>1</sup>Department of Pharmacokinetics, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan.


<sup>2</sup>Laboratory of Tissue Regeneration, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan.

<sup>3</sup>Department of Functional Molecule Kinetics, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan.

w-ochiai@hoshi.ac.jp

ADDRESS MANUSCRIPT CORRESPONDENCE TO: Dr. Wataru Ochiai\*,  
Department of Clinical Pharmacokinetics, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan.

Drug Metabolism and Disposition



**Supplemental Fig. 1 Stability of CBD in phosphoric acid aqueous solution**

The stability of CBD during the preparation of LC-MS samples was verified. In particular, since CBD is unstable under acidic conditions, its stability in a phosphoric acid aqueous solution was evaluated. Specifically, a CBD solution (10 ng / mL) was prepared using a 2% or 4% phosphoric acid aqueous solution, and incubated at room temperature for 10 min. After that, pretreatment was performed according to the protocol for preparing the LC-MS sample. Then, CBD was quantitatively analyzed by LC-MS. The analysis results were shown as mean  $\pm$  standard deviation (n = 3). Significant differences were calculated using Student's t-test. N.S., Not significant.